Candida krusei

If a yeast infection keeps coming back, or the prescription cream and pill your doctor gave you did not work, the reason may not be that you are doing something wrong. It may be that the yeast itself is the wrong species for the drug you were given.

This test identifies a specific yeast (Candida krusei, now also called Pichia kudriavzevii) on a vaginal swab. It is a less common cause of vaginal yeast infection than Candida albicans, but it shrugs off fluconazole, the single most popular yeast medication, which means standard care can fail without anyone realizing why.

What This Test Actually Detects

Candida krusei is a yeast (a single-celled fungus), not a hormone or a chemical your body makes. The test looks for the organism in a swab sample taken from the vagina. A positive result means the yeast was found growing in your sample. A negative result means it was not detected by the lab method used.

Because this yeast and a few related species can all cause similar symptoms, getting a species-level identification matters. A generic 'yeast infection' result does not tell you whether the yeast is the common, easy-to-treat kind or one that ignores the standard drug.

Why Candida krusei Matters: Built-In Drug Resistance

The defining feature of this yeast is that it is naturally resistant to fluconazole, the oral antifungal pill prescribed for almost every yeast infection. Multiple studies across Vietnam, Greece, Namibia, Yemen, Ethiopia, Uganda, and Nigeria have shown that nearly all C. krusei isolated from vaginal samples test as fluconazole-resistant. Other azole drugs in the same family, such as itraconazole and ketoconazole, also tend to perform poorly. Voriconazole is a partial exception: it keeps better laboratory activity against C. krusei than fluconazole does, though it is rarely used as a first-line vaginal treatment.

In a 12-woman series of vaginal infections caused specifically by C. krusei, most had been through several rounds of standard antifungals without success. In that same series, the laboratory found that among the azole-family drugs, the topical cream clotrimazole had the best activity, and boric acid capsules used vaginally cleared the infection in four of six treated women. Infectious-disease guidelines note that C. krusei generally responds to topical antifungal agents as a class, not only to clotrimazole. Echinocandin drugs and amphotericin B also remain active in laboratory testing across multiple studies, though these are usually reserved for severe or invasive infections.

How Common It Is on a Vaginal Swab

C. krusei is usually a small share of the yeast found in symptomatic women, but the share varies a lot by region and by population. Knowing the local pattern helps explain why species testing is worth it where the resistant strains are more common.

Source: Anh et al. 2021; Kroustali et al. 2025; Gubran et al. 2026. What this means for you: even where C. krusei is uncommon overall, if your infection is the type that keeps coming back or has not responded to standard pills, the chance that the species is the resistant one goes up. Species testing pays off most for the people whose infections are not behaving like 'textbook' yeast infections.

Symptoms and the Recurrent VVC Connection

On its own, vaginal C. krusei causes the same picture as any other yeast infection (called vulvovaginal candidiasis, or VVC): itching, burning, discharge, irritation, sometimes pain with sex or urination. You cannot tell the species from the symptoms. What you can do is notice the pattern. Women with non-albicans yeasts, including C. krusei, are over-represented in recurrent and complicated yeast infections compared with single, uncomplicated episodes.

In one U.S. clinic study of women with recurrent VVC, non-albicans species were significantly more likely than C. albicans to be associated with repeated infections. The case series that defined this organism in vaginal disease described it specifically as a cause of refractory disease after multiple rounds of azole therapy.

C. krusei in Pregnancy

Vaginal yeast colonization is more common in pregnancy. In studies from Ethiopia, Yemen, Ghana, and Serbia, C. krusei was found in pregnant women, sometimes as a notable share of the Candida present. In one Ethiopian cohort it accounted for roughly 22 out of every 100 yeast isolates among pregnant women.

Vaginal Candida colonization in pregnancy has been linked in observational research to maternal symptoms and possible vertical transmission to the newborn, with one northeast Ethiopian study reporting transmission to about 45 out of 100 colonized mothers' babies. The evidence on preterm birth is mixed. A 2020 meta-analysis of asymptomatic colonization did not find a clear link between symptomless vaginal Candida and preterm birth, but a separate meta-analysis of treatment trials reported fewer preterm births when asymptomatic candidiasis was treated, and at least one prospective cohort linked recurrent asymptomatic colonization to preterm delivery. The strongest argument for testing in pregnancy remains symptomatic infection and the need to pick an effective drug.

Asymptomatic Colonization Versus Infection

A positive swab does not automatically mean you have an infection that needs treatment. Many people carry small numbers of Candida species in the vagina without symptoms; this is called colonization. The clinical line gets crossed when there are symptoms (itching, burning, abnormal discharge) and the yeast is present in enough quantity to be the cause. A positive C. krusei test in someone with no symptoms usually does not call for treatment on its own.

What an Out-of-Pattern Result Should Make You Do Next

If you have symptoms and your swab grows C. krusei, the decision pathway is different from a standard yeast infection. Three steps usually matter.

• Get antifungal susceptibility testing: ask the lab to confirm which drugs the specific yeast is sensitive to. Resistance patterns can vary even within the species.
• Skip fluconazole as the default: standard oral fluconazole is unlikely to work. Alternatives studied in this setting include boric acid vaginal capsules and topical antifungals such as clotrimazole, both of which have shown activity in C. krusei vaginitis.
• Confirm clearance with a repeat swab: because this organism is associated with refractory disease, retesting after a course of therapy to confirm the yeast is gone is more useful than assuming symptom relief equals cure.

If infections keep returning despite targeted treatment, a referral to a gynecologist or infectious disease clinician who handles recurrent VVC is reasonable. In pregnant women and people with weakened immune systems, that referral threshold should be lower.

Why a Single Swab Is Not the Whole Story

One swab tells you what was present in one moment. The vaginal environment shifts with the menstrual cycle, recent intercourse, recent antibiotics, recent douching, and even with the season (a large Belgian lab review found vaginal Candida detection rates rose in summer, peaking around 19 out of 100 samples in June, and dipped in winter, near 14 to 15 out of 100 in December). A negative swab during a symptom-free interval does not rule out a yeast that flares periodically. A positive swab in someone with no symptoms does not automatically mean active disease.

For tracking, get a baseline swab when symptoms are present, repeat after a course of treatment to confirm clearance, and then test again with any new flare. If you have recurrent infections, swab during the flare itself rather than between episodes, because the yield is highest then.

When Results Can Be Misleading

• Recent antibiotics for bacterial vaginosis: in a randomized trial, topical metronidazole for bacterial vaginosis (a different vaginal condition, abbreviated BV) caused a sharp temporary jump in vaginal fungi, mostly Candida, that returned to baseline within about a month. A swab taken in that window may overestimate baseline yeast burden. The metronidazole vaginal gel label also lists Candida overgrowth as a known side effect.
• Self-collected versus clinician-collected swabs: studies in resource-limited settings show self-collected swabs perform comparably to clinician swabs for yeast detection, but technique still matters. Inserting the swab too shallowly or not rotating it long enough can miss yeast that is present higher in the vaginal canal.
• Asymptomatic carriage: a positive result without symptoms is most likely colonization, not infection, and should not by itself drive treatment.
• Recent intercourse or douching: both can transiently shift the vaginal microbial picture and either dilute or contaminate the sample.

How This Test Compares to a Standard 'Yeast Infection' Test

Most basic yeast tests, including the wet mount your doctor may look at under a microscope, can tell you that yeast is present but not which species. Culture with species-level identification, often confirmed by methods like MALDI-TOF mass spectrometry (a lab technique that identifies microbes by their molecular fingerprint), distinguishes C. krusei from C. albicans and other Candida species. A modern molecular vaginitis panel evaluated in a multicenter study showed very high agreement with culture for the C. glabrata and C. krusei group, with positive agreement of roughly 94 to 98 out of 100 fresh specimens and negative agreement of about 99 out of 100. The practical upshot: identifying the species is what changes treatment, not just confirming that yeast is there.